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Background: Blockade of immune inhibitory pathways is emerging as an important therapeutic modality for the
treatment of cancer. Single agent treatments have partial anti-tumor activity in preclinical models and in human
cancer patients. Inasmuch as the tumor microenvironment shows evidence of multiple immune inhibitory
mechanisms present concurrently, it has been reasoned that combination therapies may be required for optimal
therapeutic effect.
Methods: To test this notion, we utilized permutations of anti-CTLA-4 mAb, anti-PD-L1 mAb, and/or the IDO
inhibitor INCB23843 in the murine B16.SIY melanoma model.
Results: All three combinations showed markedly improved tumor control over single treatments, with many mice
achieving complete tumor rejection. This effect was seen in the absence of vaccination or adoptive T cell therapy.
The mechanism of synergy was investigated to examine the priming versus effector phase of the anti-tumor
immune response. Only a minimal increase in priming of anti-tumor T cells was observed at early time points in the
tumor-draining lymph nodes (TdLN). In contrast, as early as three days after therapy initiation, a marked increase in
the capacity of tumor-infiltrating CD8+ T cells to produce IL-2 and to proliferate was found in all groups treated
with the effective combinations. Treatment of mice with FTY720 to block new T cell trafficking from secondary
lymphoid structures still enabled restoration of IL-2 production and proliferation by intratumoral T cells, and also
retained most of the tumor growth control.
Conclusions: Our data suggest that the therapeutic effect of these immunotherapies was mainly mediated through
direct reactivation of T cells in situ. These three combinations are attractive to pursue clinically, and the ability of
intratumoral CD8+ T cells to produce IL-2 and to proliferate could be an important biomarker to integrate into
clinical studies.
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Despite expression of numerous antigens, tumor evasion
from host immunity still occurs. Over the past several
years, a working model has emerged suggesting the exist-
ence of at least two major categories of immune resistance
based on biologic features of the tumor microenvironment
[1]. One major subset shows infiltration with CD8+ T cells
at baseline, along with a specific chemokine profile and a
type I interferon (IFN) transcriptional signature, all indica-
tive of active Th1-type inflammation. These tumors ap-
pear to resist the ongoing immune response through the
dominant inhibitory effect of immune suppressive mecha-
nisms. In contrast, the other major subset lacks these che-
mokines and T cell markers and appears to escape
immune effects through immunologic ignorance or exclu-
sion. With this as a working model, one might envision
distinct immunotherapies being necessary for optimal
therapeutic effects in these two patient groups. This con-
ceptual framework is being integrated into biomarker de-
velopment as novel immunotherapies are being explored
in patients [2]. While most of these analyses have been
carried out on biopsy material from patients with advanced
melanoma, similar results are emerging in other solid tu-
mors, including lung cancer, ovarian cancer, colorectal can-
cer, breast cancer, and head and neck cancer [3-6].
Focusing in on the T cell “inflamed” tumor subset, at
least four immune inhibitory mechanisms have been iden-
tified to be involved in human specimens and validated
mechanistically in preclinical models. These are expres-
sion of the ligand PD-L1 (programmed death-ligand 1),
which can engage the inhibitory receptor PD-1 (pro-
grammed death-receptor 1) on activated T cells; presence
of the tryptophan-catabolizing enzyme indoleamine-2,3-
dioxygenase (IDO), which exploits the exquisite sensitivity
of T cells to tryptophan depletion; infiltration with FoxP3+
regulatory T cells (Tregs), which can mediate extrinsic
suppression of effector T cell function; and T cell-intrinsic
anergy, characterized by defective IL-2 (interleukin-2) pro-
duction and proliferation and driven in part through the
transcription factor Egr2 (Early growth response protein
2) [6-11]. We recently have observed that increased ex-
pression of PD-L1, IDO, and FoxP3+ Tregs in the melan-
oma tumor microenvironment is driven by infiltrating
CD8+ T cells, arguing that these mechanisms are part of
an immune-intrinsic negative feedback loop [12]. Thus,
immunotherapies aiming to uncouple these pathways may
be most effective in tumors showing the T cell-infiltrated
phenotype, during the negative feedback phase of a
chronic, smoldering immune response.
The first successful immunotherapy aiming to block a
negative regulatory pathway on T cells is the anti-CTLA-4
(Cytotoxic T-Lymphocyte Antigen-4) mAb ipilimumab,
which was approved by the FDA (Food and Drug Admin-
istration) in 2011 for treatment of patients with advancedmelanoma [13]. CTLA-4 is an inhibitory receptor also
expressed by tumor-infiltrating T cells. This success has
catalyzed extensive investigation into the potential for in-
hibitors of other immune suppressive pathways to have
clinical activity in advanced cancer patients. Early clinical
results have been reported with anti-PD-1 and anti-PD-L1
mAbs [14], IDO inhibitors [15], and Treg depletion target-
ing surface CD25 [16,17]. Numerous additional immuno-
therapeutic agents are being developed that target a
plethora of positive or negative immunoregulatory mole-
cules. These include agonistic Abs against 4-1BB, Ox40,
ICOS (Inducible T-cell COStimulator), and CD40; block-
ing Abs against LAG3 (Lymphocyte-activation gene 3),
B7-H3, B7-H4, Tim3, and KIRs (killer inhibitory recep-
tors); and the cytokines IL-7, IL-15, and IL-21 [18-26],
among others. Based on the presumption that even the
best of these agents will have modest single agent activity,
and because of the complexity of immune regulation
in vivo that involves networks of regulatory pathways, it is
envisioned that combination immunotherapies ultimately
will be required for maximal therapeutic benefit.
The prospect of investigating combination immunother-
apy doublets in early phase clinical trials in an empiric
fashion without solid mechanistic data seems daunting
and perhaps impossible to pursue based on available pa-
tient resources. We recently have assembled a framework
for logical combination of immunotherapeutic agents
based on presumed modes of action [27]. This framework
provides a motivation for testing such logical combina-
tions in suitable mouse preclinical models to aid in the
prioritization of regimens for clinical development. Mouse
models also facilitate elucidation of the mechanism by
which two interventions may be synergistic.
In the current report, we have started with αCTLA-4
mAb as a successful backbone, along with αPD-L1 and
IDO inhibition. As a tumor model, we utilized B16 melan-
oma, which does develop an “inflamed” tumor microenvir-
onment at early time points that leads to accumulation of
PD-L1, IDO, and Tregs over time [12]. We found that dou-
blets of αCTLA-4 +/− αPD-L1 +/− an IDO inhibitor each
showed improved tumor control in vivo. Mechanistic stud-
ies revealed that the major biologic effect of the successful
doublets was restoration of IL-2 production and prolifera-
tion by CD8+ T cells within the tumor microenvironment.
Our results provide support for continued development of
these combinations in patients, and also suggest a new
predictive biomarker that should be integrated into clin-
ical development.
Results
Combinatorial blockade of CTLA-4, PD-L1 or IDO pathways
results in improved tumor control in vivo
Single blockade of the immune-inhibitory pathways CTLA-
4, PD-1/PD-L1, or IDO has been shown to have modest
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improve tumor-specific immune responses in various
mouse models in vivo [28-33]. With the notion that com-
binatorial blockade might result in additive or synergistic
effects, we pursued the following experimental treatment
strategies (illustrated in Figure 1A). On day 0, B16.SIY
cells were inoculated subcutaneously in the flank of
C57BL/6 mice. After allowing the tumor cells to engraft,
therapy was initiated on day 4. The αCTLA-4 mAb (clone:
UC10-4F10-11) was given at three single time points [34].
The αPD-L1 mAb (clone: 10F.9G2) was given every other
day throughout the treatment protocol, and the IDO in-
hibitor (INCB23843) was given daily Monday-Friday via
oral gavage [35]. Treatment with single agents versus
doublet combinations was compared, using tumor growth
measured twice per week as the endpoint. For all three
double treatments, we observed improved tumor control
compared to the corresponding single regimens. In par-
ticular, the combination of αCTLA-4 and αPD-L1 resulted
in 15 complete responders out of a total of 27 treated mice
(55.5%; Figure 1B). Lower numbers of complete re-
sponders were found for the combination of αCTLA-4
and IDOi (3/16; Figure 1C) and αPD-L1 and IDOi (2/15;
Figure 1D) (complete responders see Additional file 1:
Table S1). In addition to the tested doublet therapies we
also conducted experiments using the triple combination
of αCTLA-4, αPD-L1 and IDOi, but no further improve-
ment of tumor control was observed (data not shown). To
investigate the interplay between inhibitory receptor block-
ade and IDO expression, we treated tumor-bearing mice
with αPD-L1 or IDOi alone and harvested the tumor on
the last day of therapy for analysis of IDO1 and PD-L1
transcripts by qRT-PCR. While PD-L1 mRNA expression
was not altered by either treatment, IDO1 mRNA expres-
sion was enhanced with either treatment (Additional file 2:
Figure S1). These results indicate that immune responses
augmented with αPD-L1 may secondarily lead to further
upregulation of IDO, and provide an additional rationale
for combination therapy.
To assess if the anti-tumor effect was restricted to the
presence of the model-antigen SIY we also evaluated all
three double therapies using the parental cell line
B16F10 (Additional file 2: Figure S2). Using the same
dose of tumor cells as for B16.SIY we detected a signifi-
cant delay in tumor outgrowth for all three double ther-
apies compared to the no treatment control, although
the effect was less dramatic with this less immunogenic
variant. To investigate whether the doublet therapy
would also mediated tumor control in larger more estab-
lished tumors, we delayed the initiation of treatment
until day 7. As depicted in Additional file 2: Figure S3,
delayed treatment with αCTLA-4 + αPD-L1 also resulted
in significant tumor control compared to the no treat-
ment, although therapeutic efficacy was less potent thanwith earlier treatments. Together, these results suggest
that combinatorial targeting of CTLA-4 +/− PD-L1 +/−
IDO could translate into a therapeutic advantage in vivo.
Effective combination therapies do not substantially
increase the frequency of anti-tumor CD8+ T cells in the
tumor-draining lymph node at early time points
We then turned toward understanding the mechanism
by which improved immune-mediated tumor control
might have been achieved. The major distinction was to
assess whether successful doublet therapies were first
improving the de novo priming of anti-tumor T cells in
the TdLN which then subsequently homed to tumor
sites for improved tumor control, versus directly restor-
ing or augmenting the function of CD8+ T cells already
infiltrating the tumor microenvironment. To test the first
hypothesis, we assessed the frequency of SIY-specific CD8+
T cells in the TdLN and in the spleen on day 7, using SIY-
Kb pentamer staining (Figure 2A, B). However, only min-
imal increases in frequencies of tumor-specific CD8+T
cells were observed. The functional capacity of these cells
was further assessed by IFN-γ ELISpot (Figure 1C). Using
this assay as well, we failed to detect major differences be-
tween treatment groups. Only αCTLA-4 + αPD-L1 and
αCTLA-4 + IDOi showed a statistically significant differ-
ence compared to no treatment (p = 0.0263 and p = 0.0101)
as well as to their respective single treatments (αCTLA-
4 + αPD-L to αPD-L1 p = 0.0172; αCTLA-4 + IDOi to
αCTLA-4 p = 0.0185). However, this difference did not
seem sufficient to account for the major improvement
in tumor control observed.
Recent studies have focused on the potential Treg-
depleting effect of αCTLA-4 antibody therapy [36]. To
address this possibility in our model, we evaluated Treg
frequencies using FoxP3 intracellular flow cytometry
analysis in the lymphoid organs and within the tumor.
However, neither on day 7 nor on day 14 were we able
to detect a decrease in Treg frequency in any organ
(Additional file 2: Figure S4, Additional file 1: Table S2).
This difference might be explained by different αCTLA-
4 mAb being used in various studies, and exclude a re-
quirement for Treg depletion in the efficacy of these
combination therapies in our model system.
Effective doublets result in increased frequency of
IL-2-producing and proliferating polyfunctional T cells
within the tumor
In order to address the second hypothesis of whether the
therapeutic effect was a result of reactivation of tumor-
infiltrating CD8+ T cells, we utilized an ex vivo stimulation
protocol which is designed to favor analysis of pre-
activated T cells. Responsiveness was assessed by measur-
ing proliferation (CellTrace dilution) as well as production
of IL-2, IFN-γ and TNF-α (tumor necrosis factor alpha)
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Figure 1 Pairwise combinations of αCTLA-4, αPD-L1 or IDOi blockade results in retarded tumor outgrowth. A. Schema of experimental
design illustrating the time points of drug administration throughout the experiment. αCTLA-4 was administered on day 4, 7, 10 i.p., αPD-L1 on
days 4, 6, 8, 10, 12, 14, 16 i.p. and IDOi was given on a 5 day/2 day off regimen via oral gavage Monday-Friday. B-D. Tumor outgrowth measured
in mm2 comparing the single treatment to the respective combined double treatment of B. αCTLA-4 and αPD-L1 C. αCTLA-4 and IDOi and D.
αPD-L1 and IDOi (pool of 3 experiments). Depicted are means +/− SEM of 6 mice from one representative experiment. All experiments were at
least done three times with the same overall result. Numbers next to curves indicate # of survivors/total number of mice for all experiments
done. Significance to the single treatments was tested using a two-way-Anova with Bonferroni post-test and is shown in the figure while all
treatments regimens were significantly different to the no treatment control (**** <0.0001, ** <0.01).







































































































































































Figure 2 Double regimen therapy does not result in substantially increased frequency of tumor-reactive T cells at early time points in
the periphery. A-B. Peptide/Kb pentamer staining was performed on gated CD3+CD8+ T cells, isolated from TdLN (A) or spleen (B) on day 7.
Shown are means +/− SEM of a total of 10 mice collected from two experiments. For statistical analysis, Mann–Whitney-U test was performed
comparing single treatments to double treatments (* = 0.0317 αCTLA-4 to αCTLA-4 + αPD-L1 in spleen). None of the other treatments was
significantly different to the no treatment control. C. IFN-γ ELISpot was performed on splenocytes collected on day 7. Data are shown as mean
+/− SEM from 10 mice out of two experiments with no stimulation as open bar and SIY-specific stimulation as filled bar. The Mann–Whitney-U
test was used to assess significant differences between the no treatment group and treatment regimens with * in the figure indicating significant
difference compared to no treatment. Results with αCTLA-4 were significantly different to αCTLA-4 + IDOi (p = 0.0185) and αPD-L1 was significantly
different to αCTLA-4 + αPD-L1 (p = 0.0172).
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sentative flow cytometric plot in Figure 3A, only the
therapeutic effective doublet treatments showed a detect-
able proliferation rate of CD8+ T cells in combination with
IL-2 production, and the magnitude of this effect was
striking (non-stimulated control shown in Additional file 2:
Figure S5). A statistical analysis of data spanning two in-
dependent experiments confirmed that significant ex vivo
proliferation was only observed in stimulated T cells from
mice that received the effective doublets (Figure 3B).
Modest increases in both IFN-γ and TNF-α production
were also seen; however, high production of these cytokines
by tumor-infiltrating CD8+ T cells was already observed
without treatment. Looking further at IFN-γ-producingcells in the doublet treatment groups, we observed most
IFN-γ-producing T cells were also positive for IL-2 pro-
duction and showed significantly increased proliferation
(Figure 3C), while single treatment groups showed mainly
IFN-γ single-producing cells. Comparing the stimulated
cells to non-stimulated controls confirmed that only the
double treatments were able to show increased IL-2
production and proliferation above background levels
(Additional file 2: Figure S5). These T cells also pro-
duced TNF-α, indicating a polyfunctional T cell phenotype
(Figure 3D) [37-39]. Detection of cytokine production was
dependent on re-stimulation in vitro (Additional file 2:
Figure S5). Thus, all three effective immunotherapy doublets
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Figure 3 (See legend on next page.)
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Figure 3 Double treatments restore capacity of lymphocytes within the tumor to produce IL-2 and proliferate. Tumors were harvested
on day 7 and single cell suspensions were prepared. Pools of cells from 3–5 mice were combined and subsequently stained with cell trace. Cells
were cultured with or without plate-bound anti-CD3 for 48 h then treated with anti-CD3/anti-CD28-stimulation in the presence of Brefeldin A for
6 h. Cells were then stained for production of IL-2, IFN-γ and TNF-α by intracellular flow cytometry. A. A representative FACS plot showing
proliferation via cell trace dilution on the x-axis and intracellular IL-2 staining on the y-axis. A pool of five mice was analyzed. B. Statistical analysis
of the amount of proliferating CD3+CD8+ cells in the non-stimulated (left) and stimulated (right) group. Only double treatments show a significant
increase in proliferation compared to non-stimulated and single treatments when tested with a one-way Anova. Bars represent mean +/− SEM of
a total of 4 pools collected out of 2 experiments. C. The percentages of IFN-γ+ (open bar), IFN-γ+ and IL-2+ (gray bar), and proliferating IFN-γ+IL-2+ cells
(filled bar) were calculated within the CD3+CD8+ cell population. D. The percentages of polyfunctional (TNF-α+IFN-γ+IL-2+ proliferated) CD8+ T
cells (black) compared to other less functional subsets is shown. Dark gray represents no proliferation, light gray represents no IL-2 production,
white represents no IFN-γ production for each treatment group. C and D were calculated based on the results shown in A and B.
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T cells, along with augmented polyfunctionality.
Increased frequency of polyfunctional T cells within the
tumor does not require new T cell migration
It was of interest to determine whether the presence of
CD8+ T cells showing high levels of IL-2 production and
proliferation within the tumor microenvironment follow-
ing effective immunotherapy doublets was a result of new
T cell migration into the tumor site versus re-activation of
T cells already present. To test this hypothesis, we utilized
FTY720 treatment to block the sphingosine 1-phosphate
receptor-1 and thereby prohibit T cells from exiting lym-
phoid organs. Previous studies have shown that the effect
can be detected as soon as 2 h after initial administration
and is stable for up to 4 days [40]. We therefore adminis-
tered FTY720 or control vehicle to tumor-bearing mice
on day 4, 2.5 h prior to the initiation of immunotherapies.
To control for effective depletion of circulating T cells we
assessed the number of CD3+ cells in the peripheral blood.
Overall, we detected a 90% reduction in circulating CD3+
T cells in FTY720-treated mice (Figure 4A). We then
analyzed whether IL-2 production and proliferation by
intratumoral CD8+ T cells were still restored. In fact,
comparing vehicle-treated groups (open bars) to the
FTY720-treated groups (filled bars) a similar increase in pro-
liferation and IL-2 production was observed (Figure 4B, C),
although there were some subtle differences. A modest re-
duction of proliferated/IL-2+-cells could be detected after
αCTLA-4 + IDOi treatment and a modest increase could
be observed when mice were treated with αPD-L1 + IDOi
(p = 0.0286) (Figure 4C). Nevertheless, these data strongly
suggest that the major mechanism for improved T cell
function within the tumor microenvironment following
these effective immunotherapies is through a direct effect
on CD8+ T cells already present in the tumor site.
In addition to effects on TIL function, we further inves-
tigated if tumor regression induced by treatment doublets
also could be preserved despite FTY720 administration.
To test this notion we gave FTY720 over the course of the
experiment starting at various time points (illustrated in
Figure 5A). Administration of FTY720 on day −1, prior totumor inoculation, abolished any therapeutic effect by
αCTLA-4 and αPD-L1 (Figure 5B). However, we surpris-
ingly observed that FTY720 treatment on day 4 or day 10
(after tumors were established, TILs were present, and
therapy had been initiated) only a minimal loss of tumor
control occurred (Figure 5C and 5D). These data support
the notion that the majority of tumor control induced by
αCTLA-4 and αPD-L1 is mediated by T cells that have
already left secondary lymphoid organs and presumably
reside already in the tumor site.
To further address whether increased proliferation of
tumor-infiltrating T cells was induced upon treatment
with effective immunotherapy doublets, we utilized a
short pulse of BrdU (Bromodeoxyuridine) administration
in vivo. To this end, a single dose of BrdU was adminis-
tered i.p. on day 6 and proliferation of T cells in the
tumor (Figure 6), spleen and TdLN (Additional file 2:
Figure S6) was assessed on day 7. Consistent with our
ex vivo results, we observed that the doublet-treated
mice harbored more proliferating CD8+ T cells in the
tumor site than did the single-treated groups or the mice
that received no treatment (Figure 6A). A similar effect
was also seen for CD4+ T cells, with the exception that
αCTLA4mAb single treatment also resulted in an increased
proliferation rate in this cell compartment (Figure 6B).
Taken together, these data indicate that the therapeutically
successful combination therapies of αCTLA-4 +/− αPD-
L1 +/− an IDOi resulted in increased proliferation and
reactivation of CD8+ T cells directly within the tumor
site.
Combinatorial treatments lead to prolonged persistence
and higher frequency of tumor-reactive lymphocytes in
the periphery at later time points
Effective non-specific immunotherapies are often sug-
gested to result in increased tumor antigen-specific T
cell frequencies in peripheral lymphoid organs, yet our
results above have indicated that this was not the case at
early time points in this model. We reasoned that, if
these treatments are indeed restoring T cell function
within the tumor site, then once tumors start to regress
















































































































































proliferated cells IL-2+ proliferated cells
B C
Figure 4 Restoration of IL-2 production and proliferation of
tumor-infiltrating lymphocytes in the absence of new T cell
migration. B16.SIY-bearing mice were either treated with FTY720 or
control vehicle prior to initiation of therapy, to prevent migration of
new lymphocytes into the tumor. A. Peripheral blood T cell numbers
following FTY720 treatment on the day of tumor harvest for analysis.
Open bars depict the number of CD45+CD3+ T cells detected in
200ul peripheral blood of vehicle treated mice set to 100%. Filled
bars represent the number found in FTY720-treated mice, relative to
the vehicle-treated group. B & C. Single cell suspensions from tumor
were labeled with cell trace and stimulated with plate-bound
anti-CD3 antibody for 48 h prior then with anti-CD3 and anti-CD28
in the presence of Brefeldin A. Cells were then analyzed for proliferation
by cell trace dilution and production of IL-2 via intracellular staining.
Depicted are the percentages of proliferating cells (B) or proliferating
and IL-2 producing cells (C) comparing vehicle-treated groups
(open bar) to FTY720-treated groups (filled bar). Results are shown
as the mean +/− SEM combining two experiments with each having 2
pools of 3 mice. Significance was tested using Mann–Whitney-U test
but no significant change between FTY720 and vehicle control could
be detected except for increased IL-2 production in the αPD-L1 + IDOi
treatment group (p = 0.02).
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test this notion we assayed for functional SIY-specific T
cells in the spleen on day 14 (Figure 7). Indeed, a signifi-
cant increase in the frequency of IFN-γ-producing T
cells upon SIY stimulation was observed when compar-
ing the double treatments to the single treatment or no
treatment groups. All three of the double treatment
groups show an increase in SIY-reactive cells by 2- to
even 3.5-fold higher levels compared to day 7. This ef-
fect was accompanied by increased frequency of SIY-
pentamer positive CD8+ T cells in the spleen, and also
within the tumor (Additional file 2: Figure S7). Consist-
ent with these results, re-challenge of mice 6 weeks later
that rejected the first tumor were protected against B16.
SIY (Additional file 1: Table S1). Thus, the successful
doublet treatments eventually led to a higher circulating
fraction of tumor antigen-specific T cells that likely rep-
resents a memory response.
Discussion
Our current work has indicated that doublet therapies
using either αCTLA-4, αPD-L1 and/or IDOi show a syn-
ergistic retardation of tumor outgrowth in vivo. The
major biologic correlate to this improved efficacy was
restored IL-2 production and proliferation of tumor-
infiltrating CD8+ T cells. In addition, this functional res-
toration did not require new T cell migration as assessed
using FTY720 administration. Together, these data sug-
gest that successful combination immunotherapies func-
tion, at least in part, by correcting functional defects of
T cells directly within the tumor microenvironment.
It is noteworthy that CD8+ TILs (tumor-infiltrating
lymphocytes) without any therapy showed significant
production of IFN-γ production when analyzed ex vivo.
Consistent with this observation, human melanoma me-
tastases showing a T cell-infiltrated phenotype usually
show expression of IFN-γ-induced target genes and in
many cases IFN-γ itself [41]. Recently, we have observed
that IFN-γ produced by CD8+ T cells is necessary for the
induction of the negative regulatory factors PD-L1 and
IDO within the tumor microenvironment [12]. Our
current data indicate that IDO1 is further upregulated
upon blockade of PD-L1/PD-1 interactions. Thus, the
retained ability of TIL to produce at least some IFN-γ
may in fact contribute to the negative regulatory net-
work within the tumor site that enable tumor immune
evasion.
Although several previous studies have been conducted
to investigate if combining blockade of two inhibitory
pathways could act synergistically in retarding the tumor
growth in vivo, only limited studies have addressed the
mechanism leading to this effect [30,33,42,43]. In par-
ticular the recently published studies by Duraiswamy and
colleagues (αCTLA-4 + αPD-L1) and Holmgaard et al.
no treatment 








   s.c.
617
αCTLA-4 αCTLA-4 αCTLA-4




    (D)
Day -1
          (B)
0FTY720
FTY720



















































FTY720 - Day -1
FTY720 - Day 4









Figure 5 Tumor control is largely preserved despite FTY720 administration at later time points. B16.SIY-bearing mice were either treated
with FTY720 or control vehicle prior to tumor inoculation (B), prior to initiation of therapy (C) or with the last dose of αCTLA-4 mAb on day 10
(D). A. Schematic overview of the experimental design bold arrow heads indicate initiation of FTY720 treatment, which was always carried out
through the entire experiment. B-D. Tumor outgrowth measured in mm2 comparing vehicle control (circle) to FTY720 treatment (square) on no
treatment (open) vs. αCTLA-4 + αPD-L1 (filled). B. FTY720 treatment was initiated 24 h prior to tumor inoculation. C. FTY720 treatment was given
on day 4, 2.5 h before therapy was initiated. D. FTY720 was given at the same time point as the last dose of αCTLA-4 mAb treatment. Depicted is
a representative experiment, showing mean of 5 mice +/− SEM. Significance was determined using a two-way ANOVA with Bonferroni post-test.
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combination with increased functional capacity (IFN-γ,
granzyme B) were increased with effective combinations
[44,45]. Taken together, these collective results convergeon the notion that restored function of existing TIL may
be a critical mechanism of action of these interventions.
Presence of polyfunctional T cells has been described to






















































































































Figure 6 Immunotherapy doublets result in increased BrdU incorporation by CD8+ and CD4+ tumor-infiltrating T cells in vivo. TILs were
harvested on day 7, 24 h after a single BrdU pulse in vivo, and cells were stained for BrdU along with anti-CD3, anti-CD4, and anti-CD8. Depicted
are percentages of BrdU+ cells that were CD3+ CD8+ (A) and CD3+ CD4+ (B). Data shown present the mean of a total of 5 mice from one experiment
and are representative of two independent experiments. Differences were assessed using a two-way Anova test and taking proliferation values from
spleen and TdLN into account. * indicates significantly different to no treatment and all double treatments were significantly different to their
corresponding single treatments with the exception of αCTLA-4 to both double treatments for CD4 T cell proliferation.
Spranger et al. Journal for ImmunoTherapy of Cancer 2014, 2:3 Page 10 of 14
http://www.immunotherapyofcancer.org/content/2/1/3preclinical mouse models and also in patients [37,38,46].
It is not yet known if other immunotherapy doublets will
similarly involve reactivation of T cells only within the
tumor microenvironment. Nonetheless, the data pre-
sented here show a striking importance of TIL reactiva-
tion mediated by the doublet therapies we have tested.
The mechanism leading to this could be compensatory





























































Figure 7 Immunotherapy doublets result in increased
frequencies of tumor antigen-specific T cells at later time
points in the periphery. Depicted is an IFN-γ ELISpot of splenocytes
harvested on day 14 with open bars being the un-stimulated control
and filled bars representing SIY-stimulation. Data are shown as the
mean +/− SEM from 10 mice pooled from two experiments. Statistical
analysis was done using Mann–Whitney-U test comparing all groups
to no treatment. All double treatment groups were significantly
different to their respective single treatment and when comparing
double treatments within each other a significant difference between
αCTLA4 + αPD-L1 and αPD-L1 + IDOi was observed.Recent studies have suggested that αCTLA-4 antibody
could lead to depletion of regulatory T cells selectively
within the tumor microenvironment [36,47]. In our own
hands, we were not able to detect diminished Tregs after
αCTLA4 mAb either alone or in combination, either
measuring percentage or absolute number in the tumor
site. The reason for this discrepancy is not clear, but
could be related to the use of distinct mAbs against
CTLA-4. While studies by Allison et al. were performed
with the 9D9 mAb (mouse IgG2b), our study was con-
ducted with the 4 F10 mAb (hamster IgG1). Further
work will be required to determine under what circum-
stances Treg depletion may be functionally relevant with
αCTLA-4 agents. Our own data suggest that it is not
mandatory for αCTLA-4 to deplete intratumoral Tregs
in order to have therapeutic benefit in vivo.
Our experiments with FTY720 suggest that new T cell
migration is not required in order to improve CD8+ T
cell function in response to immunotherapy combinations
in vivo. However, it is clear that successful immunother-
apies trigger tumor cell death, renewed inflammation in
the tumor site, antigen cross-presentation, and epitope
spreading [48], ultimately leading to increased T cell in-
filtration in the tumor microenvironment. This entire
cascade of events may be required for optimal tumor
elimination. Indeed, our experiments of FTY720 admin-
istration at later time points showed a modest effect on
tumor growth control. However, our results demonstrate
that new T cell migration is not required for the early im-
proved TIL function observed as well as for maintaining a
steady-state control of the tumor outgrowth. These data
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blood T cells were still present after FTY720 treatment,
which could potentially contribute to tumor infiltration.
However, an important contribution of new migration in
the presence of FTY720 would likely have been associated
with a similar 90% reduction of T cell numbers in the
tumor which is indicated by the blunted tumor control
when FTY720 is administered on day −1. In addition, our
direct in vivo analysis of TIL proliferation using BrdU ad-
ministration support the notion of rapid restoration of
TIL proliferation in situ.
Conclusions
In total, the results presented herein suggest that doub-
let combinations of anti-CTLA-4, anti-PD-1/PD-L1, or
IDO inhibition are attractive for clinical translation.
Phase I clinical trial development of the anti-CTLA-4 +
anti-PD-1 combination has already been pursued in ad-
vanced melanoma, with profound clinical response rates
observed that appear superior to single agent activity
based on historical controls [47,49]. Development of the
other combinations described herein may have a simi-
larly strong rationale for clinical testing. Our data also
suggest that proliferation and/or IL-2 production by
CD8+ TIL should be considered as a pharmacodynamic
biomarker for clinical response to these combinations.
Methods
Mice and tumor inoculation
C57BL/6 mice were purchased from Taconic Farms and
were maintained according to National Institute of Health
Animal Care guidelines. Ethical approval was obtained by
the Council for Animal Research at The University of
Chicago and followed international guidelines. B16F10
and B16-dsRed-SIY tumor cells [50] were maintained as
previously described and B16-dsRed-SIY will be speci-
fied as B16.SIY throughout the paper. On day 0 of the
experiments, 2×106 B16-dsRed-SIY cells were inocu-
lated subcutaneously into the flank of the mice. Mice
with same age and gender were used as controls.
Treatment regimens
Treatment was initiated on day 4 post tumor inoculation
with the following regimens for each drug (illustrated in
Figure 1A). αCTLA-4 antibody (clone UC10-4 F10-11,
Bio-X-Cell) was given i.p. on day 4, 7 and 10 at a dose of
100 μg/mouse. αPD-L1 antibody (clone 10 F.9G2, Bio-X-
Cell) was given i.p. (100 μg/mouse) every other day
starting on day 4 ending on day 16 post tumor inocula-
tion. IDOi (INCB23843, Incyte Corporation) was dis-
solved in 0.5% methylcellulose and administered at
300 mg/kg po QD on a 5 days on/2 days off schedule
starting on day 4 [35,51]. In the case of functional exper-
iments with an earlier endpoint, treatment regimenswere carried out as described until the day of T cell ana-
lysis. For delayed therapy the same treatment scheme was
applied starting on day 7 post-tumor inoculation, when
tumors were palpable.
Flow cytometry and antibodies
For flow cytometric analysis, spleen, TdLN, and tumor
tissues were harvested at the indicated time point or
when tumors reached a volume of 200 mm2. Single cell
suspensions were prepared and a Ficoll-Hypaque purifi-
cation step was performed for the tumor-derived cell
suspension. Following a washing step, approximately
2×106 cells were used for antibody staining. Antibodies
against the following molecules were used throughout
the paper if not otherwise indicated: CD3 (AX700, 17A2,
eBioscience), CD4 (PerCP-Cy5.5, RM4-5, Biolegend),
CD8 (APCCy7, 53–6.7, Biolegend), FoxP3 (APC, FJK-
16a, eBioscience), IL-2 (PerCP, JES6-5H4, eBioscience),
IFN-γ (APC, XMG1.2, eBioscience), and TNF-α (FITC,
MP6-XT22, eBioscience). Fixable life/dead cell discrim-
ination was performed using Fixable Viability Dye 450 or
506 (eBioscience). Staining was carried out at RT for
30 min if not indicated differently and intracellular stain-
ing was performed using the FoxP3-staining kit accord-
ing to manufacturer’s instructions (BD).
Staining of SIY-specific cells was performed using the
SIYRYYGL-pentamer (Proimmune), conjugated with
Phycoerythrin (PE), or as a non-specific control with the
SIINFEKL-pentamer. For staining, pentamers were diluted
1:50 in PBS + 10% FCS and incubated for 20 minutes at
room temperature (RT). Following a washing step, cells
were stained with specific antibodies for 30 minutes on ice
prior to fixation in 4% PFA. All flow cytometric analyses
were done using an LSR II blue instrument (BD) and ana-
lyzed using FlowJo software (Tree Star).
IFN-γ ELISpot
Splenocytes from naïve, tumor-challenged non-treated
or treated mice were harvested on day 7 or day 14 after
tumor inoculation. Single cell suspensions were prepared
and 1×106 splenocytes were assayed per well. Cells were
either left un-stimulated or stimulated with 160 nM SIY-
peptide (SIYRYYGL) or PMA 100 ng/ml and Ionomycin
1 μg/ml as positive control. After a 24 h culture period,
detection of INF-γ production was performed according
to manufacturer’s instructions.
Quantitative RT-PCR analysis
Tumor was harvested on day 16 and a single cell suspen-
sion was prepared. Approximately 107 cells were used for
RNA isolation using Qiagen RNAeasy extraction kit ac-
cording to manufactured instruction. Following cDNA
was prepared using Reverse Transcriptase kit (Manufac-
tures instructions; Applied Biosciences). Expression levels
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cific for IDO1 and PD-L1 and values were normalized
against the expression level of 18S (Roche).
Ex vivo T cell functional assays
Single cell suspensions from tumor, spleen, and TdLN
were prepared as described above. Cell numbers were
determined and cells were labeled with Cell Trace (BD)
according to manufacturer’s instructions. A maximum of
1×106 cells was plated per well on either non-treated or
anti-CD3 mAb-coated plates. Anti-CD3 mAb coating
was performed with a solution of 10 μg/ml αCD3 anti-
body (145-2C11, Biolegend) in PBS, incubated overnight
at 4°C. Following 48 h of incubation, cells were har-
vested and transferred onto newly anti-CD3-coated or
non-treated plates, along with anti-CD28 mAb (2 μg/ml)
(EL-4, Biolegend). Medium for all wells included 5 μg/ml
BrefeldinA (Sigma). Following a 6 h-incubation at 37°C,
cells were harvested and stained for surface markers
and intracellular cytokines using the technique de-
scribed above.
Treatment with FTY720
Prior to the initiation of the therapy regimens (2.5 h
pre-treatment), fingolimod (FTY720, Enzo Life Sciences)
was given to mice to inhibit lymphocyte migration out
of lymphoid organs [40]. FTY720 stock solution (10mg/ml
in DMSO) was diluted to a 125 μg/ml concentration in
PBS directly before administration. Mice received a dose
of 25 μg FTY720 or PBS containing DMSO as control via
oral gavage. Therapy was initiated the same day (2.5 h de-
layed) and mice were analyzed on day 7 to perform the
ex vivo functional assay as described above. For long-term
FTY720 administration, the dose was reduced to 5 μg per
mouse per day and was given daily throughout the experi-
ment (day-1 FTY720 was given 24 h prior to tumor inocu-
lation; day 4 FTY720 was given 2.5 h prior to therapy; day
10 FTY720 was given 2.5 h after last dose of αCTLA-4
mAb). Depletion of peripheral lymphocytes was assessed
on the endpoint of each group and was always detected to
be greater than 90% depletion.
In vivo proliferation assay
Assessment of in vivo proliferation was performed by
BrdU pulse in vivo, 24 h prior to flow cytometric ana-
lysis. Each mouse received 0.8 mg BrdU in 100 μl
injected i.p. either on day 6 or day 13 of the treatment
protocol. Mice were analyzed on day 7 or day 14, re-
spectively, and cells were prepared for flow cytometry as
described above. Following surface staining, cells were
fixed using the FoxP3 staining kit (BD). After the 30 mi-
nute fixation period, cells were incubated in 100 μl of
PBS/DNase solution (300 μg/ml) for 30 minutes at 37°C.
Cells were then washed and incubated for 30 minutes atRT with antibodies for FoxP3 and BrdU (FITC, Bu20a,
eBioscience) followed by flow cytometric analysis.
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